WO2004089351A3 - Methodes et moyens de traitement de troubles neurologiques progressifs - Google Patents
Methodes et moyens de traitement de troubles neurologiques progressifs Download PDFInfo
- Publication number
- WO2004089351A3 WO2004089351A3 PCT/GB2004/001546 GB2004001546W WO2004089351A3 WO 2004089351 A3 WO2004089351 A3 WO 2004089351A3 GB 2004001546 W GB2004001546 W GB 2004001546W WO 2004089351 A3 WO2004089351 A3 WO 2004089351A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhibitor
- neurological disorders
- miclobemid
- tacrin
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0308382.1 | 2003-04-10 | ||
GBGB0308382.1A GB0308382D0 (en) | 2003-04-10 | 2003-04-10 | Therapeutic methods and means |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004089351A2 WO2004089351A2 (fr) | 2004-10-21 |
WO2004089351A3 true WO2004089351A3 (fr) | 2005-02-17 |
Family
ID=9956617
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2004/001546 WO2004089351A2 (fr) | 2003-04-10 | 2004-04-07 | Methodes et moyens de traitement de troubles neurologiques progressifs |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0308382D0 (fr) |
WO (1) | WO2004089351A2 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008055945A1 (fr) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies |
EP2091948B1 (fr) | 2006-11-30 | 2012-04-18 | Probiodrug AG | Nouveaux inhibiteurs de glutaminylcyclase |
MX2009009234A (es) | 2007-03-01 | 2009-12-01 | Probiodrug Ag | Uso nuevo de inhibidores de ciclasa de glutaminilo. |
EP2865670B1 (fr) | 2007-04-18 | 2017-01-11 | Probiodrug AG | Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase |
RU2366430C2 (ru) | 2007-05-23 | 2009-09-10 | Виктор Иванович Рощин | Ингибиторы моноаминооксидазы, лекарственное средство и фармацевтическая композиция |
ES2548913T3 (es) | 2009-09-11 | 2015-10-21 | Probiodrug Ag | Derivados heterocíclicos como inhibidores de glutaminil ciclasa |
ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
AU2011226074B2 (en) | 2010-03-10 | 2015-01-22 | Vivoryon Therapeutics N.V. | Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5) |
EP2560953B1 (fr) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibiteurs de glutaminyl cyclase |
US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972376A (en) * | 1995-09-12 | 1999-10-26 | Hexal, A.G. | Transdermal system of tacrine/selegilin-plaster |
US20020022654A1 (en) * | 1997-05-21 | 2002-02-21 | Sloan-Kettering Institute For Cancer Research | Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
US20020150565A1 (en) * | 1999-01-08 | 2002-10-17 | Kristoffer Hellstrand | Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
-
2003
- 2003-04-10 GB GBGB0308382.1A patent/GB0308382D0/en not_active Ceased
-
2004
- 2004-04-07 WO PCT/GB2004/001546 patent/WO2004089351A2/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972376A (en) * | 1995-09-12 | 1999-10-26 | Hexal, A.G. | Transdermal system of tacrine/selegilin-plaster |
US20020022654A1 (en) * | 1997-05-21 | 2002-02-21 | Sloan-Kettering Institute For Cancer Research | Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
US20020150565A1 (en) * | 1999-01-08 | 2002-10-17 | Kristoffer Hellstrand | Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
Non-Patent Citations (3)
Title |
---|
DRINGENBERG H C ET AL: "Increased effectiveness of tacrine by deprenyl co-treatment in rats: EEG and behavioral evidence.", NEUROREPORT. 9 NOV 2000, vol. 11, no. 16, 9 November 2000 (2000-11-09), pages 3513 - 3516, XP009036771, ISSN: 0959-4965 * |
MATTHEWS T R ET AL: "NEUROPROTECTIVE EFFECTS OF CREATINE AND CYCLOCREATINE IN ANIMAL MODEL OF HUNTINGTON'S DISEASE", JOURNAL OF NEUROSCIENCE, NEW YORK, NY, US, vol. 18, no. 1, 1 January 1998 (1998-01-01), pages 156 - 163, XP001094362, ISSN: 0270-6474 * |
SCHNEIDER L S ET AL: "A DOUBLE-BLIND CROSSOVER PILOT STUDY OF L-DEPRENYL (SELEGILINE) COMBINED WITH CHOLINESTERASE INHIBITOR IN ALZHEIMER'S DISEASE", August 1993, AMERICAN JOURNAL OF PSYCHIATRY, AMERICAN PSYCHIATRIC ASSOCIATION, WASHINGTON, DC, US, PAGE(S) 321-323, ISSN: 0002-953X, XP001013252 * |
Also Published As
Publication number | Publication date |
---|---|
WO2004089351A2 (fr) | 2004-10-21 |
GB0308382D0 (en) | 2003-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004078116A3 (fr) | Inhibiteurs de la p 38 et leurs procedes d'utilisation | |
WO2006044825A3 (fr) | Inhibiteurs de la kinesine mitotique et methodes d'utilisation desdits inhibiteurs | |
WO2008021210A3 (fr) | Méthodes et compositions pour le traitement de troubles neurodégénératifs | |
WO2006001877A3 (fr) | Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs | |
GB2463833A (en) | Methods and compositions for the treatment of neurological disorders | |
WO2005118609A3 (fr) | Petits stimulateurs de molecules de croissance neuronale | |
WO2005091853A3 (fr) | Procedes et compositions pour traiter des pathologies associees a l'il-13 | |
WO2004014352A3 (fr) | Methodes de traitement de troubles dont la mediation est assuree par l'anhydrase carbonique | |
WO2005116088A3 (fr) | Methodes et compositions pour traiter des maladies et des troubles associes a des cellules exprimant siglec-8 | |
TW200510416A (en) | P38 inhibitors and methods of use thereof | |
WO2002100347A3 (fr) | Promedicaments d'analogues de gaba, compositions et utilisations desdits promedicaments | |
WO2006024018A3 (fr) | Methodes et compositions pour le traitement de la douleur nociceptive | |
WO2006055871A3 (fr) | Traitement de la sclerose en plaques | |
WO2004071431A3 (fr) | Composition et methode de traitement de troubles neurodegeneratifs | |
WO2004089351A3 (fr) | Methodes et moyens de traitement de troubles neurologiques progressifs | |
CA2416900A1 (fr) | L'utilisation combine d'un inhibiteur des lipases et d'un sequestrant d'acide biliaire pharmaceutiquement acceptable pour le traitement des maladies associees avec les niveaux eleves de cholesterol dans le plasma | |
EP1251126A3 (fr) | Derives de benzenesulfonyle a substitution fluor pour le traitment d'inflammation | |
WO2005099702A3 (fr) | Derives de r(?)-11-hydroxyaporphines et utilisations de ces derives | |
WO2004105737A3 (fr) | Compositions pharmaceutiques et procedes pour inhiber les adherences fibreuses au moyen de differents agents | |
WO2005053609A3 (fr) | Methodes d'utilisation d'inhibiteurs de desacetylase nad+ dependante | |
WO2005014814A3 (fr) | Aptameres a coiffes 5'- et 3'- et utilisations associees | |
WO2006058720A3 (fr) | Nouveaux composes pour le traitement de troubles neurologiques | |
WO2005044200A3 (fr) | Procedes et compositions pour traiter des pathologies associees a la mcp-1 | |
WO2004052404A3 (fr) | Inhibiteurs de la glycogene synthase kinase-3 | |
WO2006078336A3 (fr) | Compositions et methodes permettant de traiter et de prevenir des maladies hyperproliferatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |